Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285370 | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | completed | Phase 4 | 23 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06854653 | A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | recruiting | Phase 2 | 115 | Prescient Therapeutics, Ltd.INDUSTRY | 4 | Sep 9, 2026 | clinicaltrials |
| NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma(GoTIL-01) | not yet recruiting | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07809191 | Hair Regrowth Following Partial Thickness Removal of SSCIS | not yet recruiting | N/A | 15 | The Cooper Health SystemOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,673 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT07807878 | Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma(BAP1treat) | not yet recruiting | Phase 2 | 28 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT03380026 | Mechlorethamine Induced Contact Dermatitis Avoidance Study(MIDAS) | completed | Phase 2 | 28 | Rochester Skin Lymphoma Medical Group, PLLCOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805798 | Urinary Bladder Matrix (UBM) Registry | not yet recruiting | — | 300 | Integra LifeSciences CorporationINDUSTRY | 0 | Sep 4, 2026 | clinicaltrials |
| NCT07156227 | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07637734 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)(COVE-3) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07803406 | Multimodal Imaging of Basal Cell Carcinoma: A Usability Study | recruiting | — | 50 | Bispebjerg HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04930653 | Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | recruiting | Phase 2 | 34 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07758491 | A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 110 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03021460 | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05935995 | Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous Examination(HISTOBLOC) | completed | N/A | 42 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | suspended | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 3 | Sep 1, 2026 | clinicaltrials |
| NCT03977753 | Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts(EVAsION) | recruiting | Phase 4 | 162 | Labo'LifeINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04267861 | M7824 Related Adverse Effects in Adults With Cancer | active not recruiting | — | 232 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | suspended | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | active not recruiting | Phase 2 / Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,301 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT04904146 | Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.(BIO-MUSE) | recruiting | — | 120 | Lund University HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05779423 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06598137 | Study to Examine Lesions of the Skin Using Confocal Laser Microscopy | active not recruiting | — | 645 | LMU KlinikumOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07781449 | Topical JAK-Inhibition of Early-Stage CTCL | not yet recruiting | Phase 2 | 15 | Aarhus University HospitalOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07786376 | AI in Histipathological Diagnosis of Bcc(AI\bcc) | not yet recruiting | — | 50 | Al-Azhar UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04576091 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | active not recruiting | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02702310 | Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides | suspended | — | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06298734 | High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial | recruiting | N/A | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07682831 | Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies | recruiting | N/A | 92 | University of RochesterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07746258 | Testing Whether Skin Cancer Has Spread to Nearby Lymph Nodes(CECRE) | recruiting | N/A | 142 | Germans Trias i Pujol HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07773688 | Two-photon Fluorescence Microscopy of Dermatologic Biopsies | recruiting | N/A | 644 | University of RochesterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02824289 | Sun Safe Workplaces: A Campaign on Sun Protection Policies for Outdoor Workers Phase I(SSW) | completed | N/A | 825 | Klein Buendel, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07241585 | Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT) | recruiting | N/A | 54 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05888844 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 63 | Incyte CorporationINDUSTRY | 15 | Aug 17, 2026 | clinicaltrials |
| NCT06532279 | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | recruiting | Phase 2 | 98 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 9, 2026source: clinicaltrials